Resources

TechBio's 2024 breakthroughs proved it’s not just innovating—it’s transforming healthcare, with the UK leading the charge into a future where biology, tech, and data redefine possibilities.

Touchlight’s dbDNA technology is the first synthetic DNA technology to receive a GMP certificate globally.

Oxford Drug Design, the AI drug discovery company, has successfully completed additional in vivo validation in its potential first-in-class approach against multiple tumours.

J.P. Morgan Healthcare Conference 2025: Genomics announces Dr. Jose-Carlos Gutiérrez-Ramos as new board member to accelerate global expansion and life sciences R&D growth.

Excelra has partnered with Orogen Therapeutics, an innovative DNA-Encoded Library (DEL) and AI-driven biotechnology company currently developing a portfolio of best-in-class small molecule treatments.

In a new report, Concr team describe a ‘critical imbalance’ in a research and funding landscape where ‘other’ cancers are left in the dark.

New legislation was laid in Parliament last Thursday to modernise the regulation of clinical trials in the UK.

Innovating manufacturing processes is key to revolutionising access to advanced cell and gene therapies - this blog explores how Tolemy Bio's co-founders, Caelan and Alex, are leveraging cutting-edge technologies like AI, biochemical modelling, and omics data to overcome complex challenges and drive global scalability.

Yourgene Health (part of the Novacyt group of companies), a leading international molecular diagnostics group, announces that it has received accreditation under the new EU requirements of the in vitro diagnostic regulation (IVDR) for the Yourgene® Cystic Fibrosis Base assay.

Today, deepmirror has raised $2.4 million to simplify the adoption of AI for molecule design and enable every company to get drugs to patients faster with their accessible AI-powered platform.

Abselion, an innovator in automated analytical instrumentation that simplifies at-line protein quantification, has secured £6.6 million in Series A financing to bring its award-winning Amperia system to market.

With a new Labour Government in place, this year’s event set the stage for impactful collaboration with MPs and policymakers. Read on to learn how we’re keeping life sciences at the top of the agenda.

MultiOmic Health, a leading AI-enabled drug discovery company, announces the identification of novel patient endotypes and the development of proprietary biomarkers for stratifying diabetic kidney disease (DKD) patients.

New partnership will drive precision therapy leveraging diverse data from the Caribbean population

The Innovation in Life Sciences funding call seeks applications from organisations in the life sciences sector to create HNCDI projects that apply emerging digital technologies to industrially relevant and impactful research and innovation to further drug discovery and precision medicine in the UK.

The UK is a global leader in TechBio, drawing substantial investments and nurturing a vibrant ecosystem of talent and businesses, reveals a report launched today by the BIA.

Steve Bates OBE, CEO of the BIA, responded to the announcement of a new Regulatory Innovation Office.